Breaking Investment Walls in Femtech: Daye's Market-Disruptive Business Model

Daye, led by founder Valentina Milanova, is disrupting the market not merely as a hygiene product but as a diagnostic tool recognized by the NHS, setting a new standard in health technology. Praised by TIME magazine, this innovation highlights the structural financial barriers women founders overcome, marking a pivotal shift in the sector.

The Intersection of Regulation and Innovation

Unlike traditional sanitary products, Daye enters the category of medical devices with diagnostic capabilities, profoundly impacting operational workflows.

■NHS Validation: The company's products have achieved status as recognized and prescribable items within the UK's National Health Service.

■TIME 100 Recognition: The innovative product design secured a spot on the prestigious TIME magazine list globally.

■Diagnostic Capability: Beyond hygiene, the products fill a critical sector gap by offering health screening functionalities.

The Gender Paradox in Venture Capital

Milanova's journey exposes the three primary walls Femtech startups face against male-dominated Venture Capitalists (VC), ranging from financing access to market security.

■The Data Gap: Historical scarcity of clinical data on women's health artificially inflates the risk perception among investors.

■The Sawtooth Effect: Financing for female founders is frequently lower in volume and cuts off at earlier stages compared to their male counterparts.

■Market Misconception: Investors often underestimate the Total Addressable Market (TAM) for women's health products, overlooking growth potential.

From the perspective of an aviation logistics and secondary supply chain expert, Daye's success signals more than just product innovation; it indicates how logistical efficiency in the global distribution of medical products can be enhanced. The integration of such sensitive, diagnostic products into air cargo bridges via cold chain processes could positively impact margins in pharmaceutical logistics. The influx of investor interest into this sector suggests that the share of health technologies in the air cargo market will rise, witnessing growth in high-value cargo volumes.